聯泓新科(003022.SZ):完成EVA裝置擴能改造項目
格隆匯3月28日丨聯泓新科(003022.SZ)公佈,為實施募投項目“EVA裝置管式尾技術升級改造項目”(簡稱“EVA管式尾項目”),實現EVA裝置產能和效益提升,公司EVA裝置自2022年2月28日起停產實施技術升級擴能改造。此次改造按計劃已於2022年3月25日完成,EVA裝置於2022年3月27日成功開車。
該次能改造通過對工藝進行優化,對機組和系統進行改造,可延長裝置運行週期、降低能耗、提高催化劑轉化效率,有利於進一步優化EVA產品結構、增加EVA裝置產能。該次改造完成後,預計2022年公司EVA等主要產品產量同比會有所增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.